

Contents

ABOUT THE EDITORS — v

HISTORICAL DEVELOPMENT
AND PERSPECTIVES OF THE SERIES — vii

PREFACE TO VOLUME 19 — ix

CONTRIBUTORS TO VOLUME 19 — xix

TITLES OF VOLUMES 1–44 IN THE
METAL IONS IN BIOLOGICAL SYSTEMS SERIES — xxiii

CONTENTS OF VOLUMES IN THE
METAL IONS IN LIFE SCIENCES SERIES — xxv

Peggy L. Carver

1 METALS IN MEDICINE: THE THERAPEUTIC USE OF METAL IONS IN THE CLINIC — 1

Abstract — 2

1. Introduction — 2
2. Metal-Related Diseases — 4
3. Metals as Medicines — 5
4. Metal Ion Toxicology — 10
5. Concluding Remarks — 11

Abbreviations — 11

References — 11

Anne Robert, Françoise Benoit-Vical, Yan Liu, and Bernard Meunier

2 SMALL MOLECULES: THE PAST OR THE FUTURE IN DRUG INNOVATION? — 17

Abstract — 18

1. Introduction — 18
2. Brief Historical Overview of Chemical Drug Development — 19
3. Trioxaquines: Antimalarial Hybrid Molecules with a Dual Mode of Action — 28

- 4. Regulation of Copper Homeostasis in Alzheimer's Disease — **34**
- 5. General Conclusions — **42**
- Acknowledgments — **42**
- Abbreviations and Definitions — **42**
- References — **42**

Guido Crisponi, Valeria M. Nurchi, and Joanna I. Lachowicz

3 IRON CHELATION FOR IRON OVERLOAD IN THALASSEMIA — 49

- Abstract — **50**
- 1. Introduction — **50**
- 2. Overview on Thalassemias — **51**
- 3. Iron Chelation Therapy — **55**
- 4. Chelators in Use — **58**
- 5. Combination Therapy — **74**
- 6. New Chelators — **75**
- 7. Concluding Remarks — **79**
- Acknowledgments — **80**
- Abbreviations and Definitions — **80**
- References — **81**

Roberta J. Ward and Robert R. Crichton

4 IRONING OUT THE BRAIN — 87

- Abstract — **88**
- 1. Iron Homeostasis in the Brain — **88**
- 2. Neurodegenerative Diseases, Disruption of Iron Homeostasis, and Iron Speciation — **101**
- 3. Iron and the Immune System — **108**
- 4. Iron Chelation Present and Future Directions — **112**
- 5. Concluding Remarks — **114**
- Abbreviations — **115**
- References — **117**

Manfred Nairz and Guenter Weiss

5 INFECTIONS ASSOCIATED WITH IRON ADMINISTRATION — 123

- Abstract — **124**
- 1. Introduction — **124**
- 2. Iron, Immune Function, and Infection — **129**
- 3. Iron Administration and Infection — **135**
- 4. Concluding Remarks and Suggestions for Future Research — **143**
- Acknowledgments — **143**
- Abbreviations — **143**
- References — **145**

Amy Barton Pai

6 IRON OXIDE NANOPARTICLE FORMULATIONS FOR SUPPLEMENTATION — 157

Abstract — **158**

1. Introduction — **158**
2. Structure and Biodistribution of Intravenous Iron Formulations — **159**
3. Therapeutic Efficacy in the Dialysis Population — **164**
4. Adverse Safety Signals — **167**
5. Concluding Remarks: Gaps in Regulatory Science for Intravenous Iron Formulations — **174**

Abbreviations — **176**

References — **176**

Elzbieta Gumienna-Kontecka and Peggy L. Carver

7 BUILDING A TROJAN HORSE: SIDEROPHORE-DRUG CONJUGATES FOR THE TREATMENT OF INFECTIOUS DISEASES — 181

Abstract — **182**

1. Introduction — **182**
2. Overview of Siderophores — **183**
3. Siderophore Antimicrobial Conjugates — **191**
4. Use of Siderophore-Drug Conjugates to Alter the Spectrum of Activity of an Antimicrobial — **197**
5. Lessons Learned from the Development of Antibacterial Siderophore Drug Conjugates — **198**
6. Concluding Remarks — **199**

Acknowledgment — **200**

Abbreviations — **200**

References — **200**

Debbie C. Crans, LaRee Henry, Gabriel Cardiff, and Barry I. Posner

8 DEVELOPING VANADIUM AS AN ANTIDIABETIC OR ANTICANCER DRUG: A CLINICAL AND HISTORICAL PERSPECTIVE — 203

Abstract — **204**

1. Introduction: Antidiabetic Vanadium-Containing Compounds — **204**
2. Biological Activities of Vanadium Compounds — **209**
3. Human Studies with Vanadium Compounds — **214**
4. Commercialization of Vanadium as Antidiabetic Agent — **219**
5. What is Next? — **221**
6. Conclusions and Outlook — **224**

Acknowledgment — **225**

Abbreviations — **225**

References — **225**

Wolfgang Maret

- 9 CHROMIUM SUPPLEMENTATION IN HUMAN HEALTH, METABOLIC SYNDROME, AND DIABETES — 231**
Abstract — 232
1. The Nature of Essential Chemical Elements — 232
 2. Chromium in Mammalian Biology — 235
 3. Redox and Coordination Chemistry of Chromium Relevant to Biology — 237
 4. Chromium Metabolism — 239
 5. Low-Molecular-Weight Biological Chromium Complexes — 240
 6. Chromium Toxicity — 241
 7. Chromium in Diabetes and Metabolic Syndrome — 243
 8. Possible Resolution of Controversies in Chromium Biology — 246
- Acknowledgment — 248
Abbreviations — 248
References — 248

Keith M. Erikson and Michael Aschner

- 10 MANGANESE: ITS ROLE IN DISEASE AND HEALTH — 253**
Abstract — 254
1. Introduction — 254
 2. Manganese Essentiality — 255
 3. Factors Involved in Manganese Status — 257
 4. Manganese Neurotoxicity — 260
 5. Conclusions — 262
- Acknowledgment — 262
Abbreviations — 262
References — 263

Elizabeth A. Bajema, Kaleigh F. Roberts, and Thomas J. Meade

- 11 COBALT-SCHIFF BASE COMPLEXES: PRECLINICAL RESEARCH AND POTENTIAL THERAPEUTIC USES — 267**
Abstract — 268
1. Introduction — 268
 2. Antimicrobial Activity — 269
 3. Antiviral Activity — 275
 4. Anticancer Activity — 276
 5. Inhibiting Aggregation of Amyloid- β — 284
 6. Conclusions — 293
- Acknowledgments — 294
Abbreviations and Definitions — 294
References — 295

Jay Lopez, Divya Ramchandani, and Linda Vahdat

- 12 COPPER DEPLETION AS A THERAPEUTIC STRATEGY IN CANCER — 303**
Abstract — 304
1. Introduction — 304

2. Metals — **304**
3. Copper Homeostasis in Pathophysiology — **307**
4. Copper in Cancer — **309**
5. Preclinical Studies — **314**
6. Clinical Trials of Copper Depletion in Cancer — **318**
7. Concluding Remarks and Future Directions — **320**
- Acknowledgments — **320**
- Abbreviations — **321**
- References — **322**

Dinorah Gambino and Lucía Otero

- 13 METAL COMPOUNDS IN THE DEVELOPMENT OF ANTIPARASITIC AGENTS: RATIONAL DESIGN FROM BASIC CHEMISTRY TO THE CLINIC — 331**
- Abstract — **332**
1. Introduction — **332**
 2. Rational Design of Prospective Agents — **337**
 3. Identification and Validation of Parasite Targets — **347**
 4. Metallomics in Parasites — **349**
 5. Preclinical Studies — **350**
 6. Concluding Remarks and Perspectives — **352**
 - Acknowledgments — **353**
 - Abbreviations — **353**
 - References — **354**

Sigridur G. Suman and Johanna M. Gretarsdottir

- 14 CHEMICAL AND CLINICAL ASPECTS OF METAL-CONTAINING ANTIDOTES FOR POISONING BY CYANIDE — 359**
- Abstract — **360**
1. Introduction — **360**
 2. Naturally Occuring Cyanide — **362**
 3. Poisoning by Cyanide — **367**
 4. Metal-Containing Antidotes — **372**
 5. Concluding Remarks — **385**
 - Acknowledgment — **386**
 - Abbreviations and Definitions — **386**
 - References — **386**

SUBJECT INDEX — 393